Pharmafile Logo
Pharmafocus logo
Advanced Search

epidermolysis bullosa

Showing 3 posts of 3 posts found.

DEBRA Research and Dermaliq Therapeutics collaborate to advance treatment for rare skin disorder

May 29, 2025
Research and Development DEBRA Research, Dermaliq Therapeutics, Dermatology, epidermolysis bullosa, non-profit organisation, skin disorders

Global non-profit organisation, DEBRA Research, and clinical dermatology company, Dermaliq Therapeutics, have announced a collaboration to advance drug development for …

News
shutterstock_36423250

Promising interim Phase 3 data spurs epidermolysis bullosa trial expansion for Amryt

January 7, 2019
Research and Development, Sales and Marketing Amryt, epidermolysis bullosa, pharma, rare disease

Rare disease firm Amryt has announced interim efficacy data for its epidermolysis bullosa (EB) therapy AP101, showing that things are …

News
shutterstock_159488225

Amicus pulls plug on rare skin disease drug after Phase 3 failure

September 14, 2017
Research and Development Amicus, epidermolysis bullosa, pharma, pharmaceutical, trial failure

New Jersey-based biotech firm Amicus Therapeutics has been forced to terminate its development of its candidate for treating rare skin …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026